Artificial Intelligence company BenevolentAI has bought a drug discovery and development facility at the Babraham Research Campus in Cambridge for an undisclosed sum.
Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it be about repeat the trick with a new drug that stimulates natural kill
